PTC Therapeutics launches 9th annual STRIVE awards program

PTC Therapeutics announced the launch of the ninth annual STRIVE awards program. Through this program, PTC awards grants to patient advocacy organizations who are committed to developing initiatives that address the needs of the Duchenne Muscular Dystrophy community. Organizations may submit entries to fund 2023 projects focused on one of two categories: Innovation or Transition to Adulthood. "For 25 years, we have remained committed to supporting the Duchenne community," said Mary Frances Harmon, Senior Vice President, Corporate Relations, PTC Therapeutics. "We created STRIVE in 2015 to encourage and reward innovation by patient advocacy organizations by supporting their unique ideas and programs that help to address the needs of people living with Duchenne around the world. We are excited to see the 2023 submissions." The 2023 application process is now open and the deadline for submissions is March 17, 2023. Eligible organizations may submit proposals through an application form available on PTC’s STRIVE website. The 2023 STRIVE grant award recipients will be announced in September.